Drug Profile
Research programme: metalloenzyme inhibitors - Mycovia Pharmaceuticals
Latest Information Update: 02 Jan 2020
Price :
$50
*
At a glance
- Originator Viamet Pharmaceuticals
- Class Anti-inflammatories; Antineoplastics; Small molecules
- Mechanism of Action Enzyme inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer; Inflammation
Most Recent Events
- 27 Dec 2019 National Institute of Allergy and Infectious Disease plans a phase I trial VT 1598 for Coccidioidomycosis in USA ( NCT04208321)
- 04 Nov 2017 No recent reports of development identified for preclinical development in Cancer in USA
- 04 Nov 2017 No recent reports of development identified for research development in Inflammation in USA